Immunotherapy of cancer
Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cy...
Saved in:
Other Authors: | |
---|---|
Format: | Book |
Language: | English |
Published: |
Totowa, New Jersey
Humana Press
2006
|
Series: | Cancer drug discovery and development
|
Subjects: | |
Online Access: | Click Here to View Status and Holdings. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000nam a2200000#i 4501 | ||
---|---|---|---|
001 | wils-334029 | ||
005 | 2023018102946 | ||
008 | 230118t20062006NJU a# #001 deng D | ||
020 | # | # | |a 9781588295644 |q hardback |
020 | # | # | |a 1588295648 |q hardback |
040 | # | # | |a DLC |d UiTM |e rda |
041 | 0 | # | |a English |
060 | 0 | 0 | |a QZ 266 |
090 | 0 | 0 | |a QZ266 |b I33 2006 |
245 | 0 | 0 | |a Immunotherapy of cancer |c edited by Mary L. Disis |
264 | # | 1 | |a Totowa, New Jersey |b Humana Press |c 2006 |
264 | # | 4 | |c ©2006 |
300 | # | # | |a xii, 516 pages |b illustrations |c 26 cm |
336 | # | # | |a text |b txt |2 rdacontent |
337 | # | # | |a unmediated |b n |2 rdamedia |
338 | # | # | |a volume |b nc |2 rdacarrier |
490 | 1 | # | |a Cancer drug discovery and development |
504 | # | # | |a Includes bibliographical references and index |
520 | # | # | |a Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined |
650 | 1 | 2 | |a Neoplasm |x Design |
650 | 2 | 2 | |a Neoplasms |x therapy |
700 | 1 | # | |a Disis, Mary L. |e editor |
856 | 4 | 0 | |z Click Here to View Status and Holdings. |u https://opac.uitm.edu.my/opac/detailsPage/detailsHome.jsp?tid=334029 |
964 | # | # | |c BOK |d MD |
998 | # | # | |a 00264#1a006.2.2||00264#1b006.2.2||00300##a006.2.2||00300##b006.2.2||00300##c006.2.2||00520##a006.2.2||00520##b006.2.2|| |